Data Sheet (Cat.No.T10744)

TargetMol

SEL120-34A

Chemical Properties



CAS No. : 1609522-33-9

Formula: C15H18Br2N4

Molecular Weight: 414.14

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	SEL120-34A is a selective and ATP-competitive inhibitor of CDK8 with IC50s of 4.4 nM, 10.4 nM and 1070 nM for CDK8/CycC, CDK19/CycC and CDK9/cycT. SEL120-34A possesses antitumor activity.
Targets(IC50)	CDK
In vitro	SEL120-34A shows no obvious inhibition on CDK1, 2, 4, 6, 5, 7. SEL120-34A weakly suppresses CDK9 with an IC50 of 1070 nM. SEL120-34A is active against a panel of AML cell lines including KG-1, SKNO-1, HEL-60, MOLM-16, OciAML-2, MV-4-11, MOLM-6 and OciAML-3 cells with GI50<1 μM[1].
In vivo	SEL120-34A (30 mg/kg and 60 mg/kg; p.o.) inhibits the growth of tumors in mice bearing MV4-11 cancer cells. SEL120-34A (30 mg/kg; p.o.) arrests the growth of KG-1-derived tumors[1].

Solubility Information

Solubility	DMSO: 4.15 mg/mL (10.02 mM),Sonication is recommended. H2O: < 0.65 mg/mL (1.56mM) (insoluble) (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4146 mL	12.0732 mL	24.1464 mL
5 mM	0.4829 mL	2.4146 mL	4.8293 mL
10 mM	0.2415 mL	1.2073 mL	2.4146 mL
50 mM	0.0483 mL	0.2415 mL	0.4829 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Rzymski T, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget. 2017 May 16;8(20):33779-33795.
Zhang G M, Huang S S, Ye L X, et al. Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors. Pharmacological Research. 2022: 106464.